Tag:
PI3-K
Latest Headlines
Latest Headlines
Exelixis strikes $251M portfolio pact with Merck
Exelixis ( $EXEL ) is banking a $12 million upfront from Merck ( $MRK ) under a licensing deal covering its PI3K-delta research work. With the biotech focused squarely on its controversial late-stage
Infinity inks $488M pact on Intellikine's PI3K portfolio
Infinity Pharmaceuticals, a 2005 Fierce 15 company, has scooped up the global development and commercialization rights to a portfolio of oral PI3K inhibitors developed by Intellikine, including one
On a spree, Roche lands $175M deal for Piramed
Roche snapped up the UK's Piramed today in a $175 million deal that includes a $15 million milestone payment--the latest in a series of new acquisitions. Roche gets Piramed's programs involving
